GA
TCRT icon

Gateway Advisory’s Alaunos Therapeutics TCRT Stock Holding History

Gateway Advisory’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-102
Closed -$28K – 119
2021
Q3 		$28K Buy
+102
New +$31.2K 0.01% 116
2018
Q1 		– Sell
-117
Closed -$73K – 98
2017
Q4 		$73K Buy
+117
New +$84.1K 0.02% 93

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Gateway Advisory's TCRT Position: Q4 2021 in Review

Gateway Advisory sold out of Alaunos Therapeutics (TCRT) in Q4 2021, closing a stake of 102 shares — an estimated $28K sold.

Gateway Advisory first reported a position in TCRT in Q4 2017 and held it in 2 quarters. The position peaked at $73K in Q4 2017. 165 funds tracked by Wall St. Rank hold TCRT as of Q4 2021.

  • Gateway Advisory reported no remaining Alaunos Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Gateway Advisory sold 102 Alaunos Therapeutics shares in Q4 2021, an estimated $28K.
  • Gateway Advisory first reported a position in Alaunos Therapeutics in Q4 2017 and held it in 2 quarters.
  • Gateway Advisory's Alaunos Therapeutics position peaked at $73K in Q4 2017.
  • 165 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2021.

Based on Gateway Advisory's 13F filing for Q4 2021, filed 14 Jan 2022.